229. Autoimmune pulmonary alveolar proteinosis Clinical trials / Disease details
Clinical trials : 43 / Drugs : 34 - (DrugBank : 8) / Drug target genes : 3 - Drug target pathways : 14
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04326036 (ClinicalTrials.gov) | March 25, 2020 | 26/3/2020 | Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection | Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection | Pulmonary Alveolar Proteinosis;COPD;Idiopathic Pulmonary Fibrosis;Viral Pneumonia;Coronavirus Infection;Interstitial Lung Disease | Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF);Device: Centricyte 1000;Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution;Drug: Liberase Enzyme (Roche);Drug: Sterile Normal Saline for Intravenous Use | Black Tie Medical, Inc. | Robert W. Alexander, MD | Enrolling by invitation | 18 Years | 90 Years | All | 10 | Early Phase 1 | United States |